Hey everybody, hope you're all doing well! In this video, I talk about Pfizer's DMD gene therapy update that indicates continued Sarepta hegemony in the space. I also talk about ContraVir and their NASH drug, CRV431. I must have drank too much coffee before recording because I made more than a couple errors this time around. So, if you're an audio-only listener and hear something that doesn't sound right, double check the video version, which corrects the mistakes via captions or has it written properly even though I say it wrong (i.e. I say 3E16 when 3E13 is clearly written on the slide). Thanks to everyone for listening and do your own due diligence if you are considering investing, this is not a substitute for investment advice. www.breakingbiotech.com Follow me on twitter @matthewlepoire Support Breaking Biotech by donating to the tip jar: https://tips.pinecast.com/jar/breaking-biotech